002437 誉衡药业
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,007,062-8.41%2,135,4512,440,7322,626,0393,107,945
减:营业总成本854,148-12.65%1,906,2012,218,7952,489,2943,045,953
    其中:营业成本540,198-6.78%1,167,0821,135,9121,092,7111,338,755
               财务费用1,642173.08%(341)(1,068)31,31246,748
               资产减值损失(425)-53.11%(10,279)(4,866)(3,304)(102,397)
公允价值变动收益4,255-50.29%5,978(13,979)(17,934)(24,752)
投资收益856388.64%136,5255,251(23,438)(244,815)
    其中:对联营企业和合营企业的投资收益(123)-81.57%130,790(251)(24,755)(246,426)
营业利润183,52920.84%404,911284,853175,047(270,085)
利润总额183,38720.58%409,617283,692176,778(269,679)
减:所得税费用21,05343.56%27,26041,15248,07819,839
净利润162,33418.13%382,357242,540128,701(289,518)
减:非控股权益3,34911.54%5,4529,7818,3661,811
股东净利润158,98518.27%376,905232,759120,334(291,329)

市场价值指针
每股收益 (元) *0.07218.11%0.1720.1060.055-0.133
每股派息 (元) *------------
每股净资产 (元) *1.10821.51%1.0280.8560.7560.742
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容